Novartis Buyout of Chiron - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Buyout of Chiron


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novartis Buyout of Chiron

Novartis (Basel, Switzerland, www.novartis.com) has signed an agreement to acquire Chiron (Emeryville, CA, www.chiron.com) for $5.1 billion, after initially being rejected by the vaccine manufacturer several weeks ago. According to the merger agreement, Novartis will purchase the 58% of Chiron shares that the company doesn’t already own at $45 per share.

"Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity, so that we can better meet customer demand and address public health needs. Together with the dynamically growing diagnostics business, vaccines will form a new division, while biopharmaceuticals will be integrated into the existing pharmaceuticals business of Novartis," said Daniel Vasella, chairman and CEO of Novartis.

Novartis will gain Chiron’s blood testing business, which Novartis may use as for future molecular diagnostics development, as well as a portfolio of products for cancer and infectious disease that the company hopes will strengthen its specialty pharmaceutical portfolio and oncology pipeline.

As previously reported in Pharmaceutical Technology, Chiron has been plagued with quality problems at its European plants.  In July, the company announced that its Marburg, Germany plant in would not be supplying its “Begrivac” influenza vaccine to non-US markets for the 2005–2006 flu season. And the year-long ordeal at the company’s Evans Vaccines “Fluvirin” plant in Liverpool may finally be drawing to an end, though FDA’s approval last month of the first three post-shut-down “Fluvirin” lots does not mean that the vaccines are ready for sale.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here